MTOR and coronary artery disorder: The success of sirolimus-eluting stents for treating coronary artery disease (CAD)33, the documented anti-HIV effects of mTORi15–18,34,35, and their potential to reduce HIV reservoirs36–39 have added to interest in testing mTOR inhibitors as an adjunct to ART that may decrease monocyte-derived inflammatory mediators to ameliorate CVD risk in PLWH24.